ABBVIE
🇫🇷France
A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 72
- Registration Number
- NCT06742086
- Locations
- 🇺🇸
Acpru /Id# 272979, Grayslake, Illinois, United States
A Study to Assess Adverse Events and Effectiveness of Injections of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Change of Mid-Face Volume
Phase 3
Recruiting
- Conditions
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 272
- Registration Number
- NCT06734351
- Locations
- 🇺🇸
Pure Dermatology /ID# 258168, Metairie, Louisiana, United States
🇺🇸Aesthetic Center at Woodholme /ID# 258166, Baltimore, Maryland, United States
A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 12
- Registration Number
- NCT06722430
- Locations
- 🇺🇸
Acpru /Id# 271617, Grayslake, Illinois, United States
A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 16
- Registration Number
- NCT06722417
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC /ID# 271323, Anaheim, California, United States
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 80
- Registration Number
- NCT06718101
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
Recruiting
- Conditions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 678
- Registration Number
- NCT06712628
- Locations
- 🇩🇪
Rheumapraxis Hannover-List /ID# 273735, Hanover, Niedersachsen, Germany
🇩🇪Rheumazentrum Kupka /ID# 273631, Altenburg, Thueringen, Germany
🇩🇪Dr. Harmuth /ID# 273401, Marktredwitz, Bayern, Germany
Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 98
- Registration Number
- NCT06701331
- Locations
- 🇯🇵
Medical corporation Jun Dermatology Clinic /ID# 269953, Osaka-shi, Osaka, Japan
A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 112
- Registration Number
- NCT06698926
- Locations
- 🇺🇸
Acpru /Id# 270532, Grayslake, Illinois, United States
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 237
- Registration Number
- NCT06696755
Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada
Not yet recruiting
- Conditions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 167
- Registration Number
- NCT06692881
© Copyright 2024. All Rights Reserved by MedPath